MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma is a research paper published in Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin (2021). On theSindex it has a DataRank of 0.477. It has been cited 23 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.477
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Alberta Precision Laboratories
Grant: RS19-612
Alberta Precision Laboratories
Grant: RS10-526
National Cancer Institute
Grant: R01CA172404
National Cancer Institute
Grant: K07-CA80668
National Cancer Institute
Grant: R01CA095023
National Cancer Institute
Grant: R01 CA126841
Medical Research and Materiel Command
Grant: DAMD17-02-1-0669
National Center for Research Resources
Grant: MO1- RR000056
National Health and Medical Research Council
Grant: 310670
Australasian Biospecimen Network-Oncology
National Health and Medical Research Council
Grant: 628903
Australasian Biospecimen Network - Oncology
Cancer Institute NSW
Grant: 12/RIG/1-17
Cancer Institute NSW
Grant: 15/RIG/1-16
U.S. Defense Health Program
Grant: HU0001-16-2-0006
U.S. Defense Health Program
Grant: HU0001-19-2-0031
American Cancer Society
Grant: SIOP-06-258-01-COUN
National Cancer Institute
Grant: P30CA014089
National Cancer Institute
Grant: P50-CA135393
National Cancer Institute
Grant: R01-CA248288
University of New South Wales
Grant: NSW Health PhD Scholarship Program
Dutch Cancer Society
Grant: IKNL2014-6838
Cancer Research UK
Grant: 16561
NCI NIH HHS
Grant: K07 CA080668
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: P30 CA047904
NCRR NIH HHS
Grant: M01 RR000056
NCI NIH HHS
Grant: R01 CA248288
NCI NIH HHS
Grant: P50 CA136393
NCI NIH HHS
Grant: P30 CA015083
National Institutes of Health
Grant: 5K07CA080668-06
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERS
National Institutes of Health
Grant: 5R01CA172404-05
Identifying Prognostic Markers and Therapeutic Targets for Serous Ovarian Cancer
National Institutes of Health
Grant: 5R01CA126841-04
Regulatory T Cell Function in Ovarian Cancer
National Institutes of Health
Grant: 5R01CA095023-03
Inflammation and Ovarian Cancer
National Institutes of Health
Grant: 5R01CA248288-04
Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and Risk
National Institutes of Health
Grant: 3P30CA014089-17S1
USC COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
Translational Cancer Research Network
VGH and UBC Hospital Foundation
ALF-agreement
Breast Cancer Now
Heuer Stiftung für medizinische Forschung
Michael Smith Foundation for Health Research
Assar Gabrielsson Foundation
Westmead Hospital Department of Gynaecological Oncology
Institute of Cancer Research
Swedish Cancer Foundation
University of Pittsburgh Dean's Faculty Advancement Fund
BC Cancer Foundation
NSW Ministry of Health
Sydney West Translational Cancer Research Centre
FWCI
3.31
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Knockdown of CENPM activates cGAS-STING pathway to inhibit ovarian cancer by promoting pyroptosis
Additional file 1 of Knockdown of CENPM activates cGAS-STING pathway to inhibit ovarian cancer by promoting pyroptosis
Additional file 2 of Knockdown of CENPM activates cGAS-STING pathway to inhibit ovarian cancer by promoting pyroptosis
Additional file 2 of Knockdown of CENPM activates cGAS-STING pathway to inhibit ovarian cancer by promoting pyroptosis